The protective effect of evacetrapib was also observed in the chronic colitis model (Fig. 5), manifested in higher body weight, enhanced stem cell activity (e.g. Vil1, Muc2, Dclk1, Lgr5, and organoid diameter), better gut barrier function (e.g. Zo1, Fcgbp, Ctsz, and Zg16), and lower proinflammatory factor (e.g. Il17a,Il1b and TNFa). This evidence concerns the gene VIL1 and Chronic colitis.